about us

our sponsors

We are excited to share our success

Study Number Started Study Name Indication Participants
GSK ROTA 090 Coming Soon XXX liquid formulation of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine (XXX) HRV vaccine (Rotarix®, GSK Biologicals) ROTA Virus X
Promius DFD-06-CD-011 05/2017 An Open Label, Multicenter Study to Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing with XXX(0.025%) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis” Psoriasis 5
Verrica Pharmaceuticals VP-102-103 05/2017 A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of XXX Topical Film Forming Solution [0.7% (w/v) XXX in Subjects (2 years and older) with Molluscum Contagiosum Molluscum 5
Kimberly Clark 500-17-02 05/2017 Comparison of fecal digestive enzymes in infant aged between 0-1 years old Skin Assessment 25
Sanofi Pasteur GRC88 10/2016 Flu vaccine for children 6 to less than 36 months of age. Vaccine 95
Novavax RSV-M-301 10/2016 XXX vaccine for mother's in their third trimester of pregnancy. Vaccine Currently Enrolling
Kimberly Clark 500-16-0002 10/2016 Exploratory study to evaluate the microbial consortia of infants 9 to 12 months experiencing diaper rash when healthy. Diaper Rash 25
Roche BP30153 10/2016 Efficacy and safety of xxx in children and adolescents age 5 to 17 years with autism spectrum disorder Autism Currently Enrolling
Abbott AL19 04/2016 Effect of a supplemented infant formula on infant behavior. Nutrition
Sanofi Pasteur ADC01 04/2016 Immunogenicity and Safety of a Booster Dose of an Investigational routine vaccine in Adolescents. Vaccine 45
Sanofi Pasteur MET56 04/2016 Safety and Immunogenicity of an investigational routine vaccine in Healthy Adolescents. Vaccine 18
Pfizer A6531002 03/2016 Evaluate the Efficacy of xxx on Acute Cough in a Pediatric Population Cough Currently Enrolling
Regeneron R2222-RSV-1332 12/2015 Evaluating efficacy and safety of xxx for the prevention of RSV. Antibody 3
Sucampo SAG/0211PFC-1131 2015 Efficacy, Safety, and Pharmacokinetics of xxx in Pediatric Subjects Aged ≥ 6 Years to < 18 Years with Functional Constipation Functional Constipation
Actavis LIN-MD-62 2015 Safety and Efficacy Study of a Range of xxx Doses Administered Orally to Children, Ages 6 to 17 Years, Who Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation (FC) Constipation Currently Enrolling
Actavis LIN-MD-63 2015 Safety and Efficacy Study of a Range of xxx Doses Administered Orally to Children, Ages 7 to 17 Years, With Irritable Bowel Syndrome With Constipation (IBS-C) (i.e., Fulfill Rome III Criteria for Child/Adolescent IBS and Fulfill Modified Rome III Criteria for Child/Adolescent Functional Constipation) Constipation Currently Enrolling
Mead Johnson Project: 3602 2015 To evaluate. fecal microbiota, stool characteristics, growth, formula intake, andserious adverse events will be compared between infants assigned to one of the three study feeding groups through approximately 60 days of age Nutrition Currently Enrolling
Sanofi Pasteur MET50 2014 - 2015 To evaluate the immunogenicity and safety profile of a single dose of xxx conjugate vaccine compared to that of the licensed vaccine xxx, and when xxx conjugate vaccine is given with xxx and xxx vaccines, in health adolescents 10 to 17 years of age Vaccine 120
GSK MMR-162 2014 - 2015 Evaluate the Safety and Immunogenicity of with xxx, xxx and xxx and given on a two-dose schedule to Healthy Children in their 2nd Year of Life Vaccine 48
GSK FLUQ-QIV-022 2014 Evaluate the Immunogenicity and Safety of a Quadrivalent Influenza Vaccine xxx Compared to xxx Influenza vaccine xxx Quadrivalent, Administered Intramuscularly to Children 6 to 35 months of age Vaccine 83
Abbott AL-15 2014 - 2015 Investigate the effect of Twice Daily Consumption of an Oral Nutritional Supplement Along with Dietary Counseling for 4 weeks on Improving the Dietary Intake of Macronutrients and Micronutrients among Children with Picky Eating Behaviors aged ≥ 48month to < 73 months Nutrition 0 / Sponsor Cancelled
MK-5348045-00 2014 The ability of blood from three pediatric age groups (3 to 23 months, 2 to 11 years, and 12 to 17 years) to support thrombin-receptor agonist peptide (TRAP)-induced platelet aggregation ex vivo, as compared to adults will be estimated. The ability of MK-5348 to inhibit TRAP-induced platelet aggregation in pediatric blood ex vivo will be estimated. Vaccine 25
B1971033 2014 - 2016 To assess persistence of hSBA response for up to 48months after completion of vaccination with xxx Vaccine 18
MEM-MD-69 2013 - 2014 Safety and Tolerability of xxx in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Autism 21
MEM-MD-68 2013 - 2014 Safety and Efficacy of xxx in Pediatric Patients with Autism, Asperger’s Disorder, or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) Previously Treated with xxx Autism 10
AL13 04/2014 Healthy Term Infants Fed Milk-Based Formula with a Supplemental Carotenoid Nutrition 8
2013-1069 05/2014 Healthy Term Infants Fad Infant Formula containing DHA xxx Nutrition 11
MMR-161 09/2014 A Controlled, Multi-Center, Randomized, Observer-Blind Phase IIIA Study designed to Evaluate the Safety and Immunogenicity of xxx to xxx vaccine when Co-Administered with xxx, xxx and xxx and given on a two-dose schedule to Healthy Children in their 2nd Year of Life” Vaccine 120
SAS11538 01/2012 A 6-Month Safety And Benefit Study Of Inhaled xxx Combination Versus Inhaled xxx In The Treatment Of 6,200 Pediatric Subjects 4-11 Years Old With Persistent Asthma” Asthma 8
MTA55 08/2012 A Phase 4, Multi-Center, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of xxx When Administered to Healthy Subjects at 9 months and Concomitantly with xxx at 15 to 18 Months of Age” Vaccine 70
M5I02 06/2012 A Phase 3, Multi-Center, Randomized, Open label Study to Evaluate the Safety and Immunogenicity of xxx and xxx and xxx Vaccine Adsorbed Combined with Inactivated xxx Compared to xxx and xxx Vaccine Adsorbed) + xxx Vaccine xxx as the 5th Dose in Children 4 to 6 Years of Age” Vaccine 105
V59_40 01/2012 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of a Combined xxx, xxx Vaccine and xxx in Healthy Adolescents when Administered with xxx. Vaccine 23
B1971011 05/2011 A phase 2, randomized, controlled, observer/blinded trial, to assess the safety, tolerability, and immunogenicity of Gardasil (HPV) vaccine and XXX vaccine when administered concomitantly in healthy subjects Age ≥11 To <17 Years Vaccine 30
B1971015 05/2011 A Phase 2, Randomized, Controlled, Observer-Blinded Trial, To Assess The Safety, Tolerability, And Immunogenicity Of xxx Vaccine And xxx Vaccine When Administered Concomitantly In Healthy Subjects Age ≥11 To <17 Years Vaccine 66
419-006 05/2011 A Phase 3 Randomized, Partially Double-Blind, Active-Comparator-Controlled, Lot-to-Lot Consistency Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of xxx in Healthy Infants When Given at 2, 4, and 6 Months Concomitantly with xxx and xxx Vaccine 300
09.03 09/2010 Effects of 100% Whey, xxx Infant Formula with xxx Ion Signs and Symptoms of Colic Formula 0 / Sponsor Cancelled
V59_36 09/2010 A Phase 3b, Randomized, Open-Label, Multi-Center Study to Evaluate the Safety and Immunogenicity of 2 or 3 Doses of xxx Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of xxx Administered in the Second Year of Life Vaccine 45
09.04 09/2010 Assessment of growth of infants fed starter formulas with modified protein and symbiotics Formula 82
AK66 04/2010 Growth and Tolerance of Healthy Term Infants to a New Infant Formula Formula 65
A0221066 01/2010 An Open-Label, Dose-Escalating Study Of The Pharmacokinetics, Safety And Tolerability Of xxx In Pediatric Overactive Bladder Patients Aged 8-17 Years UTI 10
MI-MA213 10/2010 An Observational Prospective Study to Assess Respiratory Cohort 2 Syncytial Virus (RSV) Respiratory Events Among Premature Infants (32 to 35 week Gestational Age) Outcomes and Risks Tracking Study RSV 30
AK54 06/2008 Comparative Gastrointestinal Tolerance of Various Infant Formulas in Healthy Term Infants Formula 55
AK62 04/2008 Tolerance of Healthy Term Infants Fed Infant Formulas Formula 60
A2501060 03/2008 An Open-Label Study to Evaluate the Safety of xxx for up to 1 Year in the Treatment of the Cognitive Dysfunction Exhibited by Children with Down Syndrome - Follow-Up to a 10 Week, Double-Blind, Placebo-Controlled Trial Down's Syndrome 25
A2501059 03/2008 A 10-Week, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy and Safety Of xxx In The Treatment Of The Cognitive Dysfunction Exhibited By ChildrenWith Down Syndrome Down's Syndrome 25
AK53 08/2007 Tolerance of Healthy, Term Infants to Infant Formulas Formula 65
BLI-AX-001 01/2007 A Double-Blind, Randomized, Parallel, Multicenter Study of xxx Oral Solution in the Treatment of Gastroesophageal Reflux Disease (GERD) Symptoms in Infants Age 30 Days-1 Year GERD 50
AK44 01/2007 Pilot Tolerance and Bone Status of Healthy, Term Infants Fed Infant Formulas Formula 50
AK39 06/2006 Evaluation of Growth, Safety and Tolerance of a New Infant Formula in Healthy Full-Term Infants Formula 65
EFC6820 08/2006 Efficacy and Tolerability of xxx in the treatment of children aged 6-17yrs with ADHD associated insomnia Insomnia 15

LOCATIONS

3262 Salt Creek Circle Lincoln, NE 68504
3901 Pine Lake Rd, Suite 210 Lincoln, NE 68516
8201 Northwoods Drive Lincoln, NE 68505
1336 West A St, Suite B Lincoln, NE 68522

Phone: 402-465-5600
Fax: 402-327-6074

OFFICE HOURS

9am to 5pm Monday through Friday

CONNECT

Phone: 402-465-5600
Fax: 402-327-6074